Retatrutide
Retatrutide is an investigational compound studied for its ability to target three metabolic hormones at once to support weight loss.
Quick facts
Research Use Only
Phase 3 Ongoing
What is Retatrutide?
Retatrutide is an investigational compound currently in clinical trials. It is designed to target three different hormone receptors at the same time: GLP-1, GIP, and glucagon. Researchers are studying how this triple action might suppress appetite, improve how the body uses sugar, and increase the amount of energy the body uses. It is not yet approved for public use.
Common Uses
In a Phase 3 clinical trial, retatrutide was associated with a 28.7% average weight loss at 68 weeks in adults with obesity.
In a Phase 2 trial, retatrutide was associated with normal liver fat levels in 86% of participants with metabolic liver disease after 24 weeks.
Research suggests retatrutide acts on GLP-1 and GIP receptors to support potential improvements in insulin sensitivity.
Ongoing Phase 3 trials are studying retatrutide for its potential effects on broader metabolic health and obesity-related joint issues.
Studies & Clinical Research
A deep dive into the science, clinical trial data, and real-world implications of the most powerful weight-loss peptide ever
Retatrutide targets three hormone receptors at the same time—GLP-1, GIP, and glucagon. In clinical trials, retatrutide was associated with suppressed appetite, improved blood sugar control, and increased energy expenditure.
Retatrutide is an investigational compound, and long-term safety data is still being collected in Phase 3 trials. In early trials, it was generally well-tolerated, with mild stomach issues like nausea being the most common side effects. It is not approved for use outside of clinical trials.
In Phase 3 trials, the most significant weight loss results with retatrutide were observed over 68 weeks. Because it is an investigational compound, it is not available for general use.
Yes. Retatrutide is currently only available through official clinical trials. A clinical trial coordinator or licensed provider must evaluate your eligibility to participate.
Have a question you don’t see answered?
Ready to take the next step?
Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.